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Abstract
Background: Identification of the epitopes targeted by antibodies that can neutralize diverse HIV-1 strains can
provide important clues for the design of a preventative vaccine.
Methods: We have developed a computational approach that can identify key amino acids within the HIV-1
envelope glycoprotein that influence sensitivity to broadly cross-neutralizing antibodies. Given a sequence
alignment and neutralization titers for a panel of viruses, the method works by fitting a phylogenetic model that
allows the amino acid frequencies at each site to depend on neutralization sensitivities. Sites at which viral
evolution influences neutralization sensitivity were identified using Bayes factors (BFs) to compare the fit of this
model to that of a null model in which sequences evolved independently of antibody sensitivity. Conformational
epitopes were identified with a Metropolis algorithm that searched for a cluster of sites with large Bayes factors on
the tertiary structure of the viral envelope.
Results: We applied our method to ID50 neutralization data generated from seven HIV-1 subtype C serum samples
with neutralization breadth that had been tested against a multi-clade panel of 225 pseudoviruses for which
envelope sequences were also available. For each sample, between two and four sites were identified that were
strongly associated with neutralization sensitivity (2ln(BF) > 6), a subset of which were experimentally confirmed
using site-directed mutagenesis.
Conclusions: Our results provide strong support for the use of evolutionary models applied to cross-sectional viral
neutralization data to identify the epitopes of serum antibodies that confer neutralization breadth.
Keywords: HIV, Antibodies, Neutralization sensitivity, Epitope prediction, Evolutionary model
Background
A successful HIV-1 vaccine is likely to require the induc-
tion of neutralizing antibodies that can prevent infection.
HIV-1 entry into host cells is mediated by the HIV-1
envelope glycoprotein, which forms a trimeric structure
on the surface of the virus. Each of these envelope
“spikes” consists of three identical, non-covalently
associated heterodimers of surface gp120 and transmem-
brane gp41. Antibodies that bind the envelope can be
detected within eight days of infection [1]. However,
neutralizing antibodies that specifically bind the trimeric
form of the envelope and prevent cell entry are slower
to develop and appear about 3–6 months after infection
[2-7]. Importantly, these early neutralizing antibodies
preferentially bind the autologous virus and are therefore
strain-specific [4,5,7-9]. In contrast, recent studies have
revealed that 15-20% of infected people are able to
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of genetically diverse HIV-1 strains [10-12]. However,
these broadly neutralizing antibodies are generally
only produced 2–4 years after infection [12,13]. Al-
though these neutralizing antibodies may not protect
against disease progression [12,14], the fact that the
host B cell response has the potential to generate
such broadly reactive neutralizing antibodies against
HIV-1 has led to renewed interest in the development
of a preventative vaccine that elicits similar types of
antibodies [3].
The HIV-1 envelope has evolved an array of mecha-
nisms that hinder binding by neutralizing antibodies.
The envelope glycoprotein is genetically variable, confor-
mationally flexible and heavily glycosylated, resulting in
either escape from antibody recognition or shielding of
neutralization sensitive sites [4,15,16]. The narrowness
of the initial response, together with the plasticity of the
envelope protein, allows escape variants to evolve rapidly
in the infected individual [4,5,8,17]. Nevertheless, fitness
constraints preclude complete resistance and certain
regions of envelope remain vulnerable to antibody neu-
tralization [18]. Recently, new highly potent monoclonal
antibodies have been isolated that define targets on the
HIV envelope. This includes the PG9/PG16 monoclonal
antibodies that recognize an epitope involving V2 and
V3 created by the trimeric structure [19], the PGT anti-
bodies that mostly rely on a glycan at position 332 in the
C3 region of gp120 [20], the VRC01 monoclonal anti-
body that targets the CD4 binding site [21] and the gp41
membrane proximal external region-specific antibody
10E8 [22]. These broadly neutralizing monoclonal anti-
bodies greatly expand our understanding of the conser-
ved epitopes on the envelope, which were previously
defined by IgG1b12 against the CD4 binding site, 2G12
against the glycan shield in the outer domain and 4E10
and 2 F5 that recognize distinct epitopes in the mem-
brane proximal external region of gp41 [23-27].
Broad serum neutralization could potentially be medi-
ated by a polyclonal set of neutralizing antibodies that
accumulate over time and target several distinct regions
of envelope [13,28]. Alternatively, the gradual focusing
of the B cell response onto functionally conserved re-
gions of envelope could be responsible for the potent
neutralization of diverse HIV-1 isolates in some individ-
uals. Although it is likely that both scenarios occur in
infected subjects [29], the latter possibility is supported
by the recent identification of monoclonal antibodies
whose neutralization breadth matches that of the corre-
sponding serum [19-21]. The identification and charac-
terization of epitopes that are targeted by antibodies in
broadly neutralizing sera is a key step in the design of
immunogens that can potentially induce broad neutraliz-
ing antibodies against HIV-1.
B cell epitope prediction is complicated by the conform-
ation-dependent nature of antigen-antibody binding. Al-
though more than 90% of antibody epitopes are estimated
to be conformational in nature, most experimental and
computational methods are designed to identify only
linear epitopes [30-32]. Here, we present a novel compu-
tational method that uses cross-sectional neutralization
sensitivity and sequence data from a large panel of viruses
to predict sites that lie within antibody epitopes. Similar
data were analyzed by Gnanakaran et al. [15], who devel-
oped phylogenetically-corrected methods for identifying
signature amino acid sites in envelope that were associated
with neutralization phenotypes. While their method re-
quired discrete neutralization phenotypes, our method
permits the use of continuous neutralization measures,
which should enhance statistical power. More recently,
Georgiev et al. [33] developed a technique to deconvolute
the antibody specificities in polyclonal sera. However, their
method does not identify amino acid positions associated
with neutralization sensitivity and does not account for
the phylogenetic relationships between viruses.
Our method incorporates neutralization sensitivities
directly into a phylogenetic model of molecular evolu-
tion. Amino acid sites at which the pattern of evolution
correlated with changes in neutralization sensitivity
across the phylogenetic tree were identified. We hypoth-
esized that many of the sites that were associated with
changes in the neutralization sensitivity of multiple
viruses lie within antibody epitopes. In order to identify
sites in the alignment that were most likely to influence
neutralization sensitivity, we used Bayes factors to
compare the fit of a model that allows the amino acid
frequency at each site to depend on neutralization sen-
sitivities (epitope model) to that of a model which
assumes independence (non-epitope model). A contigu-
ous set of sites on the primary sequence that favored the
epitope model provided evidence for a B cell epitope
(which could be linear or conformational), while a set of
sites with large Bayes factors that were clustered in
three-dimensional space provided evidence of a confor-
mational epitope. We used this approach to predict
epitopes targeted by the broadly neutralizing antibodies
present in the sera of seven HIV-1 subtype C-infected
individuals enrolled in the CAPRISA Acute Infection
study [12]. All sites with strong support were then tested
experimentally using mutagenesis studies. We found that
our model accurately predicted amino acid residues that
were targeted by broadly neutralizing serum antibodies,
including those present in V2, the glycan shield and the
membrane proximal external region.
Results
We have previously identified sera from seven HIV-1
subtype C-infected women in the CAPRISA 002 cohort
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post-infection against a panel of 42 viruses from subtypes
A, B and C [12]. In order to assess neutralization sero-
types more comprehensively (as part of the Neutralization
Serotype Discovery Project of the Collaboration for AIDS
Vaccine Discovery), these sera were tested against a much
larger panel of 225 envelope-pseudotyped viruses, inclu-
ding subtypes A (n=10 ),B( n=56 ),C(n=69 ),D(n=6)
and G (n=6), as well as several circulating recombinant
forms (CRFs) (n=78). For each pseudovirus, the
neutralization titer of a subject’s serum was recorded as
the reciprocal of the maximal plasma dilution that could
inhibit 50% of viral entry (denoted as ID50). The
neutralization breadth, as measured by the overall per-
centage of viruses neutralized (ID50>20) by each serum,
ranged from 82% (CAP255) to 94% (CAP206) (Figure 1A).
Notably, the titers of CAP256 (which neutralized 93% of
the panel viruses) were considerably higher than those of
any other serum, with an ID50 exceeding 10, 000 against
some viruses (Figure 1B). Serum from CAP8, CAP177,
CAP206 and CAP255 showed no clear subtype specificity.
In contrast, the CAP248, CAP256 and CAP257 sera
neutralized subtype C viruses better than the subtype B
panel viruses (Wilcoxon tests of median titer, p<0. 00 1) .
Since our method takes the phylogenetic relationships
between the panel viruses into account, the preferential
neutralization of certain HIV-1 clades by these serum
antibodies did not bias our results.
Identification of amino acid residues targeted by the
broadly neutralizing serum of CAP256
We first analyzed the data from CAP256 which showed
the highest neutralization titers (Figure 1) mainly attrib-
uted to antibodies targeting a PG9/PG16-like quaternary
(trimer-specific) epitope [34]. These antibodies were
shown to be dependent on the R166 and K169 residues
in the V2 region with F159, N160, L165, D167, and
K171 also contributing to the epitope, though to a lesser
extent. Consequently, these data provided a set of well-
characterized true-positive sites that could be used to
test whether our method had the capacity to detect key
sites within neutralizing antibody epitopes.
Given a coding sequence alignment and a phylogenetic
tree for the virus panel, we used evolutionary models to
identify sites in the alignment at which the pattern of
evolution along branches of the tree was dependent on
the neutralization titer of the virus at the tip of each
branch (see Methods for details). Scaled Bayes factors
(denoted as Bk for HXB2 amino acid position k) were
used to compare the fit of a model where the equilib-
rium frequency of the “reference” amino acid at each site
depended on neutralization titer to that of a null model
of independence. The reference amino acid at each site
was defined by identifying a “reference sequence” that was
sensitive to the antibodies present in a particular serum
sample. Because our model predictions depended on the
reference amino acid at each site, several reference se-
quences were considered for each serum.
Our model provided striking evidence of an association
between neutralization sensitivity and the amino acids
present at sites 166 (B166= 25.4) and 169 (B169=10.7) (see
Figure 2). Both of these sites are critical for the formation
of the quaternary epitope targeted by the serum antibodies
of CAP256 [34]. In particular, we found that viruses with
an arginine at position 166 or a lysine at position 169 were
significantly more sensitive to CAP256 serum neutra-
lization than viruses with other amino acid residues at
these positions, supporting previous studies [34]. Use of
three other reference sequences identified the same 2
residues (Additional file 1: Figures S1A-C). Experimental
confirmation for the role of 166R and 169K in CAP256
neutralization is shown in Table 1 where mutations at
both sites resulted in major reductions in neutralization
titers, particularly in the CAP45 backbone.
We also found weak evidence of an association with
neutralization sensitivity at sites 162, 163, 167, 176, 177,
181, 183, 187, 193 and 194 in V2 (2 <Bk<6). The fact
that our model assigns moderately large scaled Bayes
factors to this cluster of sites is encouraging. However,
there were many other sites throughout gp120 and gp41
with scaled Bayes factors in this intermediate region
(2<Bk < 6), as might be expected when multiple model
comparisons are performed. To account for the fact that
multiple model comparisons were carried out, we com-
puted the local false discovery rate (LFDR) associated with
the Bayes factor at each site (see Methods). As expected,
the large Bayes factors at sites 166 and 169 were highly
likely to be true positives with low LFDRs of 0.0001 and
0.083, respectively (Table 1). The next highest scaled Bayes
factor was 5.95 (LFDR=0.492) at site 2 when the
reference sequence contained an arginine at this position.
Since this scaled Bayes factor was much smaller than
those at positions 166 and 169 and below our sig-
nificance threshold of 6, we did not regard any other
amino acid positions as significantly associated with
neutralization titer.
Prediction of sites targeted by PG9/PG16-like antibodies
In order to explore the utility of our model, we tested
two additional sera predicted to have a similar specificity
to CAP256, but with considerably lower titers. Four sites
were found to be strongly associated (Bk ≥ 6) with neu-
tralization by CAP8 serum antibodies (see the scaled
Bayes factors in Table 1; plots shown in Additional file 1:
Figure S2). The largest scaled Bayes factor of 11.9 was
observed at position 295, a potential N-linked glycosyla-
tion (PNG) site. However, replacing the asparagine at
this position in the TRO backbone did not reduce ID50
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Figure 1 ID50 titers for each serum sample. (A) Heat map of ID50 titers clustered by the viral phylogeny. The percentages below the heat map
indicate the percentage of panel viruses that were neutralized (ID50>20) by the antibodies in each serum. (B) Histograms of the natural
logarithm of ID50 titer. The distribution for CAP256 was notably different from that of the other sera.
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associated with neutralization sensitivity (B316 =9.1).
Mutation of this residue in the ConC backbone resulted
in a large drop in ID50 titers from 11,000 to 6,000.
Mutations in the V3 region are known to modulate
neutralization sensitivity of the conserved V2 epitope
recognized by PG9/PG16-like antibodies. Therefore,
although no sites within the conserved C-strand in V2
were detected, the detection of residue 316 in V3 was
consistent with a known neutralizing specificity in the
CAP8 serum, which was previously shown to target a
PG9/PG16-like trimer-specific epitope [12,35]. Sites 24
(B24=6.4) in the envelope signal peptide and site 535
(B535=6.0) in gp41 were also found to be associated
with titer, though we do not expect these to contribute
to CAP8 antibody neutralization and therefore did not
test them experimentally.
For CAP257 serum, we identified signals at positions
166 (B166 =6.3) and 295 (B295=7.0) in the V2 and V3
regions of gp120, respectively, and at positions 648
(B648 = 6.1) and 702 (B702 = 6.2) in gp41. Sites 166,
295 and 648 were tested with site-directed mutagen-
esis and the substitution of alanine at site 648 in the
RHPA backbone was found to reduce ID50 titers by
more than 2 fold (Table 1). Serum from this individual has
previously been shown to contain at least two distinct
antibody specificities; one targeting a PG9/PG16-like
trimer-specific epitope, followed by a second that overlaps
the CD4 binding site (Wibmer et al., submitted). Although
our evolutionary model did identify position 166 in the V2
region, this could not be experimentally validated (Table 1
and Additional file 1: Figure S3). However, introduction of
an R166A mutation completely abrogated neutralization
by serum from an earlier time point, confirming the
existence of a PG9/PG16-like specificity in CAP257
(Wibmer et al., submitted).
Prediction of sites associated with N332-dependent
broadly neutralizing antibodies
Two CAPRISA sera that targeted another broadly neu-
tralizing antibody epitope were tested with our model.
The Bayes factors for CAP255 serum identified three
sites in the C3 region of gp120 (sites 332, 334 and 351)
(see Figure 3; plots for alternative reference sequences
are provided in Additional file 1: Figure S4). Two of
these sites in close proximity on the primary sequence
were strongly associated (Bk ≥ 6) with neutralization titer,
namely positions 332 and 334. For site 332, all of the
reference sequences contained an asparagine at this
position and yielded a large scaled Bayes factor of 8.0,
suggesting that viruses with this amino acid were sen-
sitive to CAP255 antibody neutralization. This result
was supported by site-directed mutagenesis in the Q23
(4.0 fold) and TRO (2.9 fold) envelope backbones but
not in ConC. Our model predictions also showed a large
scaled Bayes factor of 6.8 at site 334, which forms part
of the same N-linked glycosylation motif, when the
reference residue was serine. The involvement of this
site was confirmed experimentally in the TRO envelope
backbone (>12.4 fold) only. The Q23 reference sequence
has a threonine at this position which yields a Bayes
factor close to zero, suggesting that this amino acid is
not enriched among the sensitive viruses in the panel.
This is perhaps surprising, given that a threonine at this
position also permits the attachment of an N-linked
glycan at site 332. The identification of 332 and 334 as
CAP256 serum with ConC reference sequence
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Figure 2 Scaled Bayes factors for CAP256. Neutralization titers were strongly associated with sites 166 and 169 when the ConC reference
sequence was used. These sites have previously been shown to contribute significantly to the epitope targeted by CAP256 antibodies [12].
Shaded regions indicate the degree of evidence for an association with ID50: white indicates no or negligible evidence, light grey indicates
moderate evidence and dark grey indicates strong evidence [55]. Sites that were strongly associated with ID50 are annotated with their HXB2
position and the amino acid found to be enriched among sensitive (high titer) viruses at that site.
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mapping data showing that these antibodies are
dependent on the N332 glycan in the C3 region [12],
similar to many of the recently described PGT monoclo-
nal antibodies [20].
In addition to sites 332 and 334, we also obtained a
large scaled Bayes factor of 6.82 at position 351 when
this site contained an isoleucine in the reference se-
quence for the CAP255 data. Our model also predicted
site 837 in gp41. While we do not expect that this
position lies within a CAP255 epitope, it is possible
that amino acid changes in gp41 contribute to neu-
tralization sensitivity by influencing epitope accessi-
bility through conformational changes to the envelope
complex [36,37].
In addition to the three sites in the C3 region with
Bk≥ 6, several surrounding sites were weakly associated
with CAP255 neutralization sensitivity and had 2<Bk<6
for at least one reference sequence (see Figure 3). Many of
these residues were in close proximity on the tertiary
structure as illustrated in Figure 4A. Indeed, residues in
this spatial region were found to have higher posterior
probabilities of belonging to a conformational epitope
after applying our three-dimensional epitope prediction
algorithm (see Figure 4B). Site 332 had the highest pos-
terior probability of 0.191 and neighboring residues had
slightly lower posterior probabilities.
It is possible that the association with neutralization
sensitivity at some of these spatially-proximal sites might
be a consequence of compensatory mutations. To investi-
gate this, we used the Bayesian graphical model of Poon
et al. [38] to tease apart direct and indirect correlations
between residue positions and ID50 titer. A network graph
indicating the direct associations (with posterior probabil-
ities>0.75) of all sites with Bk>4 using the CAP255 data
is shown in Figure 5. We found that all of these sites were
directly associated with ID50 titer and therefore that none
of our predicted associations were likely to be due to com-
pensation for resistance-imparting mutations elsewhere.
Resistance to CAP255 serum could therefore be attributed
to mutations at several sites that either constitute the
binding interface of a single antibody or represent inde-
pendent targets of multiple antibodies. This was the case
for all sites with Bk>6 across all sera (see the supporting
information for each serum).
For CAP177 serum, our model predicted four sites
that influenced neutralization sensitivity with strong
support (Bk ≥6). These included sites 209 in the C2
region, 332 and 334 in the C3 region and 683 in the
membrane proximal external region of gp41 (Table 1,
Additional file 1: Figure S5). Asparagine was observed at a
significantly higher frequency at position 332 among
neutralization-sensitive viruses than among neutralization-
resistant viruses, similar to CAP255 (B332=7 . 3 ) .T h i sr es u lt
was experimentally validated in the Q23, TRO and, to a
lesser extent, ConC envelope backbones (see Table 1). Our
model also predicted that a serine residue at site 334,
which forms part of the same N-linked glycosylation motif,
imparts neutralization sensitivity, with a large scaled Bayes
Table 1 All sites with scaled Bayes factors≥ 6
Serum HXB2
position
Reference
residue
‡
Scaled Bayes
factor (LFDR)
Backbone ID50
fold effect
CAP256 166
† Arg 25.4 (0.0001) CAP45 261.3*
ConC 22.2*
169
† Lys 10.7 (0.083) CAP45 365.8*
ConC 15.3*
CAP8 24 Met 6.4 (1.000) NT
295 Asn 11.9 (1.000) TRO 0.4
316
† Thr 9.1 (1.000) ConC 1.8
535 Ile 6.0 (1.000) NT
CAP257 166 Arg 6.3 (0.738) ConC 1.8
295 Asn 7.0 (0.665) Q842 0.1
648 Glu 6.1 (0.757) Du156 1.2
RHPA 2.9*
702 Leu 6.2 (0.747) NT
CAP255 332 Asn 8.0 (0.622) Q23 4.0*
TRO 2.9*
ConC 0.2
334 Ser 6.8 (0.750) TRO >12.4*
ConC 0.3
351 Glu 6.8 (0.750) NT
837 Phe 10.1 (0.366) NT
CAP177 209 Thr 8.8 (0.388) TRO 0.4
332
† Asn 7.3 (0.573) ConC 1.7
Q23 11.0*
TRO >2.8*
334
† Ser 7.8 (0.511) ConC 2.1*
TRO 0.2
683 Lys 6.3 (0.689) NT
CAP206 150 Met 6.7 (0.457) NT
655 Lys 7.3 (0.384) NT
CAP248 85 Val 6.5 (1.000) NT
340 Glu 6.0 (1.000) ConC 2.2*
CAP45 0.6
651 Asn 7.4 (1.000) ConC 2.0*
CAP45 1.3
Du156 2.4*
659 Asp 8.9 (1.000) ConC 2.9*
CAP45 0.5
†Sites with q≤ 1/3 based on the method of Gnanakaran et al. [15].
‡Amino
acid found to be significantly enriched among sensitive (high titer) viruses
based on our evolutionary model. *Fold effect≥ 2. NT= Not tested.
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residue with an alanine in the ConC backbone resulted in
a >2 fold decrease in ID50 titer, although this same muta-
tion produced a five-fold increase in ID50 titers with the
TRO backbone. Nonetheless, these experimental results
confirmed the importance of this site as a determinant of
neutralization titer. This is in line with experimental map-
ping studies in CAP177, which, like CAP255, showed the
presence of antibodies recognizing 332-dependent PGT-
like epitopes, though these differ subtly from those in
CAP255 in their dependence on variable loops [12,35].
There was, however, less evidence of an association
with titer at spatially-proximal sites and consequently
our three-dimensional epitope prediction method did
not identify a similar region of high posterior prob-
abilities for CAP177 as for CAP255. The prediction
that position 209 (B209=8.8) influenced neutralization
sensitivity to CAP177 sera could not be experimen-
tally validated in the envelope backbone tested here.
We did not attempt to validate site 683 (B683=6. 3 ).
Overall, our model was very effective in predicting
sites associated with sensitivity to PGT-like antibodies
that are dependent on the glycan at position 332 in
both CAP255 and CAP177. These specificities appear
to be relatively common among broadly neutralizing sera
[19,29,33,39], although strain-specific N332-dependent
antibodies have also been reported [40].
Identification of sites forming part of epitopes in gp41
For CAP206, our model predicted two amino acid
positions that were strongly associated with antibody
neutralization across six different reference sequences
(see Table 1 and Additional file 1: Figure S6). One of
these predictions, site 150 (B150=6.7), was in the V1
region, while the other prediction, site 655 (B655=7.3),
was near the membrane proximal external region in
gp41. The latter prediction is consistent with available
mapping data, showing that neutralization breadth in
CAP206 is mediated largely by antibodies targeting this
region [39]. This is further supported by the recent isola-
tion from CAP206 memory B cells of the moderately
broad monoclonal antibody, CAP206-CH12, which rec-
ognizes an epitope in the membrane proximal external
region [41].
For the final serum examined, CAP248, mapping
studies have shown that the serum antibodies target a
quaternary epitope that has not yet been defined, but is
not PG9/PG16-like [12]. We found associations between
the amino acids at positions 651 (B651=7.4) and 659
(B659=8.9) adjacent to the membrane proximal external
region of gp41 and neutralization sensitivity (Table 1
and Additional file 1: Figure S7). In particular, our model
revealed that viruses with an asparagine at position
651 or an aspartic acid at position 659 exhibited
greater sensitivity to CAP248 antibody neutralization
than other viruses. Interestingly, both sites lie be-
tween two gp41 positions that are known to affect
antibody binding to epitopes in gp120 [36,37]. Both
of these predictions were confirmed experimentally
(see Table 1). Our evolutionary model also identified
sites 85 (B85 =6.5) and 340 (B340=6.0) in gp120 as
significantly associated with titer. The prediction at
position 340 was confirmed by mutagenesis, while site 85
was not tested experimentally.
Discussion
We have developed a novel computational approach
to identify amino acid residues in HIV-1 envelope
CAP255 serum with ConC reference sequence
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Figure 3 Scaled Bayes factors for CAP255. There was strong evidence of an association with ID50 titer at sites 332, 334 and 351 when the
ConC reference sequence was used. The predictions at sites 332 and 334 were tested and validated experimentally (see Table 1). There were
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antibodies. The method can be used to identify neu-
tralizing antibody epitopes when neutralization sensi-
tivity to the serum is available for a large panel of
sequenced viruses. Such data will become increasingly
available as large-scale efforts to investigate HIV-1
neutralization serotypes are undertaken. The method
is an extension of the evolutionary model of Lacerda
et al. [42] and allows the distribution of amino acids
at each site to depend on neutralization sensitivities
at the tips of the branches along a phylogeny. Bayes
factors were used to assess the fit of this model at
each site relative to that of a model in which the
virus evolves independently of the antibody response.
Large Bayes factors indicated positions in the align-
ment where neutralization sensitivity was significantly
associated with amino acid composition after account-
ing for the phylogeny.
This method was applied to neutralization datasets of
seven HIV-1 subtype C serum samples that were pre-
viously shown to have neutralization breadth [12]. In
addition, epitope mapping data was available for six of
the seven samples [12,34,39], providing an opportunity
to compare our computational method with experimen-
tal approaches to epitope mapping. For each serum sam-
ple, envelope sequences and neutralization sensitivities
A
B
Figure 4 Three-dimensional predictions for CAP255. (A) Amino acid residues that were weakly (2≤Bk< 4), moderately (4≤Bk< 6) and
strongly (Bk≥6) associated with ID50 titer using the ConC reference sequence are shown with light, intermediate and dark green, respectively.
There is evidence for a cluster of sites with moderately large Bayes factors on the three-dimensional surface, as might be expected of a B cell
epitope. (B) Posterior probabilities of a conformational epitope using the three-dimensional Metropolis algorithm. The surface of the protein
(PDB ID: 2B4C) was shaded from dark blue (posterior probability= 0) to red (posterior probability=1) according to the posterior probability
assigned to each amino acid residue. There was evidence for a conformational epitope involving the C3 region (residues in the light blue region
have posterior probabilities of approximately 0.2).
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pseudoviruses. Our model identified two to four sites
per sample and 24 predictions across all sera that were
strongly associated with neutralization sensitivity. We
were able to confirm ten of the fifteen sites that we
tested using site-directed mutagenesis. In many cases,
these corresponded to sites that had previously been
linked to antibody neutralization in these and other
broadly neutralizing sera. This included two positions in
the V2 region (166 and 169) that contributed to a
trimer-specific PG9/PG16-like epitope [34] and the
glycan at site 332 that is crucial for the epitope targeted
by many of the PGT monoclonal antibodies [12,20,35].
We also identified two novel sites near the membrane
proximal external region in gp41 that influenced neutra-
lization sensitivity to the CAP248 sera and another two
positions in the same region that are associated with
sensitivity to CAP206 and CAP257 antibodies. The
CAP257 serum was unusual in that neutralization
breadth has been shown to be mediated by at least
two distinct specificities, which arose sequentially and
then waned (Wibmer et al., submitted). The three-
year time point, which was used for this study, fell
between two specificities when the titers for each
were lower than their peak. Nonetheless, our model
found a significant association with titer at position
166, which is consistent with the PG9/PG16-like spe-
cificity that developed initially.
Our model is similar to the one developed by
Gnanakaran et al. [15] who applied the phylogenetically-
corrected method of Bhattacharya et al. [43] to identify
signature positions in the HIV-1 envelope that were
associated with antibody neutralization. While their
contingency table-based approach requires that viruses be
classified into discrete neutralization phenotypes, our
evolutionary model permits the use of continuous neu-
tralization measures, which is likely to enhance the
statistical power to detect an association. In addition, our
method naturally accounts for the uncertainty of the
unknown ancestral sequences, while their approach treats
the reconstructed sequences as observed data. In contrast
to our current model implementation, the method of
Gnanakaran et al. [15] does not require the specification
of a neutralization sensitive sequence for each serum
sample and can be used to identify combinations of amino
acids and sites that influence antibody neutralization
sensitivity. Although such combinations could be accom-
modated straightforwardly in our model, it would be com-
putationally expensive to do so and the increase in the
number of tests performed could greatly reduce statistical
332
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Figure 5 Bayesian evolutionary-network model for CAP255 [38]. The red node corresponds to ID50 titer and all other nodes represent sites
in the HIV-1 envelope. Nodes with scaled Bayes factors> 6 are shaded in dark green, while nodes with scaled Bayes factors between 2 and 6 are
shaded in light green. An edge connecting two nodes indicates that there is a direct association between the two nodes. Edges are labeled with
the estimated posterior probability of an interaction between the nodes they connect. Only sites with scaled Bayes factors> 4 or posterior
probabilities of an association with such a site> 0.75 are shown. Since all of the sites with Bayes factors>4 are directly connected to the ID50
node, none of the predicted associations could be attributed to compensatory mutations.
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amino acid residues at each site based on a selection of
pseudoviruses (reference sequences) that have previously
been shown to be sensitive to the antibodies of a particular
serum sample.
For comparison with our results, we applied the
method of Gnanakaran et al. [15] to our neutralization
datasets. Of the 24 associations that we identified across
the seven sera (see Table 1), five were also detected with
the method of Gnanakaran et al. [15] using a q-value
threshold of 1/3 and three alternative neutralization classi-
fications (see Additional file 2: Table S3). We were able to
detect four of our fifteen experimentally-validated associa-
tions using this technique. The method of Gnanakaran
et al. [15] yielded a further thirteen predictions with q≤1/
3 across the seven sera, though we did not attempt to
validate these experimentally.
The effects of experimental amino acid mutations in
different backbones were highly variable, as has been
observed in numerous previous studies [12,20,29,34]. This
reflects the extremely complex nature of neutralization
escape. Our evolutionary model makes the simplifying
assumption that each site evolves independently and, as
such, does not account for context-specific effects that
may alter substitution rates differentially in distinct
viruses. This assumption does not hold in vitro where the
fold effect of mutagenesis depends not only on the
mutated residue, but also on the entire backbone context.
In addition to mutations directly within epitopes, neu-
tralization resistance may also be meditated by steric
shielding of epitopes and distal changes, which may be
compensatory or may drive conformational changes that
limit accessibility of antibodies to epitopes. While our
model may detect non-causal associations between titer
and the amino acid composition at sites that experience
such compensatory mutations, it is not expected that
these associations will be confirmed by mutagenesis. In
order to assess the extent to which this was the case, we
implemented the evolutionary network model of Poon
et al. [38]. Across all seven sera, we found that all sites
with scaled Bayes factors greater than six directly
coevolved with titer, indicating that our predictions cor-
responded to potential resistance sites and not compensa-
tory mutations.
To account for multiple testing, we computed the
local false discovery rate (LFDR) associated with each of
our predictions; that is, the probability that a site is
incorrectly found to be associated with titer given the
codon data at the site and the prior probability of no
association (see Methods). To compute the prior prob-
ability of no association, we first estimated the probabil-
ity of obtaining a positive scaled Bayes factor when no
association exists by randomly shuffling the assignment
of titers to sequences. For computational reasons, we
were only able to perform 100 such permutations.
We then made the conservative assumption that a
site that is truly associated with titer will always have
a positive scaled Bayes factor. Consequently, the
LFDR estimates reported in Table 1 should be inter-
preted as upper bounds on the true LFDRs. As such, many
of these estimates are quite large. Indeed, the estimates of
the LFDRs for all CAP8 and CAP248 predictions were 1,
since the conservative prior probability of no association
was 1 for both of these sera. The true LFDRs for
these predictions will likely be less than this.
To identify amino acid positions that collectively
provide support for the existence of a conformational
epitope, we introduced a model in which all sites within
a sphere on the tertiary structure evolved according to
the epitope model, while the evolution of all other sites
was described by the non-epitope model. A Metropolis
algorithm was used to explore the posterior density of
the center and radius of the sphere and thereby deter-
mine the most likely location and size of a conform-
ational epitope on the envelope structure. This approach
predicted a known epitope in the C3 region targeted by
the CAP255 neutralizing serum. No three-dimensional
clusters with high posterior probability were predicted in
CAP177, CAP248 or CAP206. The three-dimensional
prediction algorithm did, however, find evidence for an
epitope targeted by the CAP256, CAP8 and CAP257
antibodies in the V3 region of gp120 (largest posterior
probability of 0.367, 0.654 and 0.361, respectively; see
Additional file 1: Figures S1E, S2E and S3D). A more
realistic model would treat a B cell epitope as a patch
of surface-exposed amino acids and estimate the loca-
tion, shape and size of this surface area. Additional
structures including the scaffolded V2 structure [44]
and particularly future structures of trimeric forms of
t h ee n v e l o p ew o u l dg r e a t l ye n h a n c et h ep o w e ro ft h i s
approach.
The unobserved titers at all ancestral nodes represent
a missing data problem. Unfortunately, integration over
all of these unknown variables is not a computationally
feasible option for large phylogenies. Instead, one must
resort to an imputation procedure. In the model pre-
sented here, the ancestral nodes were all assigned the
median value of the observed titers at the tips of the
phylogeny. We obtained very similar results when codon
evolution along the internal branches was modeled
with a standard, titer-independent MG94×HKY85 model.
Although the internal branches alone cannot provide
evidence of an association with neutralization sensitivity
in our current model implementation, they are inform-
ative about the parameters of the evolutionary model and
may therefore increase the power of our method to detect
associations based on evolution along the terminal
branches. This further distinguishes our approach from
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Gnanakaran et al. [15], that only consider mutational pat-
terns along the terminal branches. An alternative ap-
proach is to reconstruct the ancestral titers based on a
model of titer evolution. We investigated this strategy
using the ancestral reconstruction method of Felsenstein
[45]. Briefly, the ancestral titer at each parent node in the
phylogeny was imputed as the average of the observed
and estimated titers at its two daughter nodes, weighted
by the reciprocal of their branch lengths after accounting
for the variability of the titer estimates. We obtained many
additional predictions using this procedure, presumably
because the inferred ancestral titers provide more infor-
mation than the median and are treated as if observed
without error (see Additional file 2: Table S4 and
Additional file 1: Figure S8). We therefore consider our use
of median titers at the ancestral nodes as conservative.
Existing models of quantitative phenotype evolution, in-
cluding the Brownian motion-based model of Felsenstein
[45] and the Ornstein-Uhlenbeck process [46], assume con-
tinuous sample paths and are therefore not appropriate for
modeling neutralization titer that undergoes abrupt and
discontinuous changes in equilibrium level induced by spe-
cific amino acid substitutions. Modeling the evolution of
quantitative traits with discontinuous paths is an active
area of research [47]. A more realistic model of titer
evolution may enhance the statistical power of our
method by providing further evidence of genotype/
phenotype associations along internal branches of the
phylogeny. Our model can readily accommodate an-
cestral titers inferred by any means and we are cur-
rently investigating alternative methods for inferring
these unknown titers.
To our knowledge, this is the first attempt to identify
conformational B cell epitopes on a tertiary structure
based on the evolutionary history of a panel of viruses.
In principle, our model could be combined with other
structure- and mimotope-based methods that assign
scores to residues based on their structural properties
and peptide-binding affinities.
Conclusions
Our method is an effective tool for detecting sequence
positions that contribute to neutralizing antibody sensi-
tivity, even within quaternary epitopes on the trimeric
envelope complex. However, in the absence of infor-
mation on the host immune responses experienced by
each of the viruses in the panel, we cannot determine
whether the correlations between amino acid frequen-
cies and neutralization phenotype at these sites are a
consequence of selective immune pressure or random
genetic drift. Furthermore, sites that influence neu-
tralization sensitivity through insertions and deletions
that alter epitope binding affinity or through shifts in
glycosylation patterns will not be detected by our
approach [4,8]. Nonetheless, our results provide strong
support for the use of evolutionary models as a
means to identify key residues in complex B cell epi-
topes. The conformational nature of these epitopes
renders them difficult to discover with currently available
computational tools.
Methods
Ethics statement
The CAPRISA Acute Infection study was reviewed and
approved by the research ethics committees of the
University of KwaZulu-Natal (E013/04), the University
of Cape Town (025/2004) and the University of the
Witwatersrand (MM040202). All participants provided
written informed consent for study participation.
Neutralization and sequence data
We analyzed neutralization datasets from seven HIV-1
subtype C-infected women from the CAPRISA 002
Acute Infection Study [48]. These subjects, namely
CAP8, CAP177, CAP206, CAP248, CAP255, CAP256
and CAP257, all developed broadly cross-neutralizing
antibodies against HIV-1 [12]. The potency of the serum
antibodies collected at 3 years post-infection from each
subject was measured against a multiclade panel of 225
envelope-pseudotyped viruses as part of the Neutralization
Serotype Discovery Project (NSDP) (see Figure 1A). For
each pseudovirus, the neutralization titer of a subject’s
serum was recorded as the reciprocal of the maximal
plasma dilution that could inhibit 50% of viral entry
(ID50). The data for CAP256 was used to decide on the
optimal modeling strategy.
HIV-1 gp160 sequences from 225 panel viruses were
codon aligned with the hidden Markov model implemented
in the HIVAlign tool of the Los Alamos National Laboratory
(LANL) HIV database (http://www.hiv.lanl.gov/content/
sequence/HIV/HIVTools.html). Nucleotide sites at which
more than 10% of the sequences contained gaps were
removed by deleting the corresponding codon. In doing
so, we restricted our analyses to the regions of envelope
that are readily aligned [15]. The resulting alignment
contained 818 codons, spanning HXB2 envelope posi-
tions 1 to 856, excluding sites 13–16, 31, 137–149,
189–190, 310–311, 354–355, 395–408, 460–462 and
514, and including four insertions relative to HXB2.
The HIV-1 gp160 alignment is provided as Additional
file 3: Dataset S1. The Genbank accession numbers and
neutralization titers for the envelope sequences are pro-
vided in Additional file 4: Dataset S2.
The alignment was screened for recombination using
GARD [49] with a general time reversible nucleotide
model and among-site rate variation modeled with a
three-category general discrete distribution. A single
Lacerda et al. Virology Journal 2013, 10:347 Page 11 of 18
http://www.virologyj.com/content/10/1/347recombination breakpoint was detected at nucleotide
position 1331. Although recombination can be accommo-
dated straightforwardly in our modeling approach by
using different phylogenies for each non-recombinant
fragment, this would have required the estimation of 447
additional branch length parameters. Rather than attempt
this, we conducted a simulation study to assess whether a
single recombination breakpoint was likely to substan-
tively affect our results. Briefly, we simulated 10 align-
ments with a single recombination breakpoint using
NetRecodon [50] and evolved log titers along the phyl-
ogeny corresponding to the largest non-recombinant
partition of each alignment according to Brownian mo-
tion. We applied our method to each of the 10 simulated
datasets ignoring recombination and did not observe any
false positives, suggesting that our results are robust to
recombination at this level.
A single, maximum likelihood phylogeny for the
panel of viruses was inferred with PhyML [51] by
specifying a general time reversible model of nu-
cleotide substitution and an estimated proportion of
invariable sites. Site-to-site variation in the evolution-
ary rate of the variable sites was modeled by a four-
category discrete gamma distribution with unit mean.
Subtree pruning and regrafting and nearest neighbor
interchange were used to search the tree space for the
optimal topology, starting with a BioNJ tree and five
random trees. The root was identified by including an
outgroup of SIV and HIV-1 groups N, O and P reference
sequences obtained from the LANL HIV sequence
database.
Evolutionary models
Our computational approach to identifying sites targeted
by broadly neutralizing antibodies is an extension of the
method of Lacerda et al. [42], which was originally devel-
oped to predict T cell epitopes by identifying escape sites
where viral evolution correlated with the immune type of
the host. Here, we did not have information on the host
conditions under which each of the panel viruses evolved
and therefore could not infer immune escape per se.
Instead, we identified amino acid positions in HIV-1 enve-
lope that influenced sensitivity to antibody neutralization
across a phylogeny. This was achieved by specifying an
evolutionary model that allowed the amino acid equilib-
rium frequencies at each site to depend on neutralization
titer. To avoid estimating 19 frequency parameters at each
site, we selected a neutralization-sensitive virus, which we
refer to as the “reference sequence,” and modeled only the
equilibrium frequency of the amino acid present in this
sequence at each site. Reference sequences were
selected on the basis of high neutralization titers
(which varied depending on the potency of each serum
sample) and the availability of cloned envelopes for
later validation studies. Where possible, the early
autologous virus (isolated from the individual from
whom the broadly neutralizing serum was obtained)
was also used, as most of these viruses are known to
be sensitive to the broadly neutralizing antibodies that
develop later. The reference sequences used for each
serum and their Genbank accession numbers are pro-
vided in Additional file 2: Table S1.
We adapted the evolutionary model of Halpern and
Bruno [52] in which the instantaneous rate of codon
substitution q
k
ij at site k is parameterized as the product
of the mutation rate μij and the probability of fixation f
k
ij
relative to that of a neutral mutation; that is, q
k
ij ∝ μij×f
k
ij /
(1/N)f o rc o d o n si and j and effective haploid population
size N. Assuming a time-reversible model of codon substi-
tution, the authors showed that the fixation probability of
a mutation from codon i to codon j with relative selective
advantage 1+s, s ≪ 1, can be written as
f
k
ij ¼ N−1
ln
νk
j μji
νk
i μij
  
1−
νk
i μij
νk
j μji
; ð1Þ
where νk
j is the equilibrium frequency of codon j at site k.
We parameterized the site-specific equilibrium frequen-
cies as
νk
j ¼
γk  
πj
πΓ
if j∈Γ
1−γk
  
 
πj
1−πΓ
if j∉Γ;
8
> <
> :
ð2Þ
where γk is the equilibrium frequency of the reference
amino acid at site k, πj is the equilibrium frequency
of codon j in the absence of selection, Γ represents
the set of codons that encode the reference amino
acid and πΓ = ∑ i ∈ Γπi. The factor involving the πj
terms distributes the reference amino acid frequency
among the codons that encode it in such a way as to
maintain the codon usage bias observed over the entire
alignment.
We used an HKY85 model for the mutation rate μij,
with the nucleotide equilibrium frequencies estimated
empirically from the full alignment. Because we fitted
this model to coding sequences, our estimates will not
only reflect the mutational process, but will also capture
selection induced through the genetic code. We do not
expect that our model results will be sensitive to this
misspecification. Ideally, the mutation parameters should
be estimated from non-coding nucleotide sequences
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mutation model were used to construct F1 × 4 estimates
of the codon frequencies πj expected in the absence of
selection.
Assuming a time-reversible mutation process, substi-
tuting (2) into (1) yields f
k
ij =1/N, and hence s =0, for all
mutations that do not involve a substitution of the
reference residue for or by another amino acid. This
formulation therefore permits only directional selection
that alters the codon equilibrium frequencies νk
j based
on the frequency γk of the reference amino acid at site k.
Nonsynonymous mutations that do not involve the
reference amino acid would have the same fixation
probability (1/N) as synonymous mutations and would
therefore be modeled as selectively neutral. However,
nonsynonymous mutations at different sites are likely to
evolve under purifying and diversifying selection that
alters the fixation probabilities without affecting codon
frequencies. To accommodate this in our model, we
parameterize the fixation probability of a nonsynon-
ymous mutation at site k as ωk ×1 / N. A value of ωk =1
indicates that nonsynonymous and synonymous muta-
tions are fixed with the same probability at site k in
the absence of directional selection. Values of ωk <1
and ωk > 1 imply purifying and diversifying selection
at site k, respectively. The codon substitution rates
are then defined as
qk
ij∝
μij if synonymous
μijωk if nonsynonymous; i∉Γ; j∉Γ
μijωk
In
γk
1−γk
  
,
πΓ
1−πΓ ðÞ
 !
1−
πΓ
1−πΓ ðÞ
 
γk
1−γk
  
 ! if nonsynonymous; i∉Γ; j∈Γ
μijωk
In
1−γk
  
γk
 
1−πΓ ðÞ
πΓ
  
1−
1−πΓ ðÞ
πΓ
 
1−γk
  
γk
   if nonsynonymous; i∈Γ; j∉Γ
0i f i and jdifferat > 1ntposition:
8
> > > > > > > > > > > > > > > > > > > > <
> > > > > > > > > > > > > > > > > > > > :
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A similar codon model that distinguishes between
diversifying and directional selection was recently con-
sidered by Murrell et al. [53].
To identify codon sites associated with sensitivity to
antibodies, we allowed the equilibrium frequency γk of
the reference amino acid to depend on neutralization
titers. More specifically, let γ0k be the equilibrium
frequency of the reference amino acid at site k among
sensitive (high ID50 titer) viruses and let γ1k denote this
frequency for resistant (low ID50 titer) viruses. We set
γk =p γ0k +(1 – p) γ1k, where p ∈ [0,1] is a measure of
neutralization sensitivity that is monotonically increasing
in ID50 neutralization titer. Since the frequency of
the reference residue among sensitive viruses was
expected to be at least as large as that among resist-
ant viruses, we constrained γ0k≥ γ1k where equality
implied that a site was not associated with antibody
neutralization.
For the model defined in Equation (3), nonsynon-
ymous substitutions toward the reference amino acid
occur at a higher rate if the relative equilibrium fre-
quency of the reference residue γk/(1-γk) is larger than
its expected value in the absence of directional selection,
πΓ/(1-πΓ). Substitutions in the opposite direction are
favored if the converse is true. Thus, a neutralization-
resistant virus (p close to 0) would be more likely to
substitute the reference amino acid for another residue at
sites where γ0k>γ1k. Similarly, substitutions in favor of the
reference residue will be more likely at these sites among
neutralization-sensitive viruses (p close to 1). This pattern
of evolution would reduce the prevalence of the reference
residue among resistant viruses and increase its frequency
among sensitive viruses, consistent with our expectation
of sites associated with antibody neutralization.
The value of p along each branch of the phylogeny
was determined by the neutralization titer of the
sequence at the tip of that branch. This parameter may
be specified by selecting appropriate titer thresholds and
setting p= 0 if the titer is high (sensitive), p=1 if the
titer is low (resistant) and setting p equal to the pro-
portion of classified viruses that were sensitive when
the titer is an intermediate value or unknown. The
method of Gnanakaran et al. [15] classifies viruses as
neutralization sensitive or resistant by applying such a
threshold. Here, ID50 titer was treated as a continuous
variable and mapped onto the [0,1] scale to obtain values
for p. Due to the skewness of the ID50 titer distribution,
we defined p=[t – min(t)]/max[t – min(t)], where t is the
natural logarithm of titer. When the titer was unknown,
such as at all ancestral nodes, we set p equal to its median
value among all sequences with observed titers. We also
considered imputing the unknown titer values using the
method of Felsenstein [45] (see Discussion).
Although Equation (3) defines a time-reversible model
along each branch of the phylogeny, the process is not
time reversible when considered over the entire tree.
Consequently, the location of the root node and initial
codon frequencies must be specified for valid likelihood-
based inference. This specification is trivial when the
median titer is used to define p at all nodes with
unknown titers, since any interior node that is not the
immediate ancestor of a leaf node can then act as the
root [42]. However, identification of a specific node as
the root is required when the imputed titer values differ
between ancestral nodes, such as with Felsenstein’s
method of reconstruction [45].
Given an inferred topology and F1 × 4 codon equilib-
rium frequencies, all model parameters, except γ0k and
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HyPhy [54] with ωk drawn from a three-category general
discrete distribution. Fixing the set, θ, of these parameters
at their estimated values, the probability p(xk| θ, γ0k, γ1k)
of the codon data xk at site k can be computed under
the model in Equation (3) for any pair (γ0k, γ1k):
0 ≤ γ1k≤ γ0k ≤ 1 using Felsenstein’s pruning algorithm.
To compute the likelihood of our epitope model, we
treated γ0k and γ1k as nuisance parameters with a flat
joint distribution and integrated them out of the like-
lihood function using the adaptive numerical integra-
tion routine available in the cubature R package. We
also computed the likelihood of a non-epitope model
that does not allow for an association between an
alignment site and neutralization sensitivities by setting
γ0k=γ1k=γk and integrating γk out of the likelihood
function with γk ~ U(0,1).
The data-based evidence in support of the epitope
model relative to the non-epitope model at site k was
then assessed using the scaled Bayes factor
Bk ¼ 2ln
 
LE θjxk ðÞ
LNðθjxkÞ
!
;
where LE(θ | xk)a n dLN(θ | xk) are the integrated likeli-
hoods under the epitope and non-epitope models,
respectively. Kass and Raftery [55] suggest that a value of
2<Bk<6 can be interpreted as positive, but weak evidence
against the null model, while Bk≥6 indicates strong
evidence against the null model. We used the latter
criterion to identify sites for experimental validation.
By performing model comparisons at each of 818 amino
acid positions per serum, we anticipated that some sites
with Bk≥6 would be false positives. To address this issue,
we computed the local false discovery rate associated
with each of our scaled Bayes factors. The local false
discovery rate (LFDR) is defined as the probability of the
null (non-epitope) model given the codon data xk at site k
[56]. For each site identified as significantly associated
with neutralization titer, the LFDR indicates the probabil-
ity that the site has been classified incorrectly, given the
data xk and the prior probability π0 of the null model. The
LFDR for site k may be computed by observing that
1−LFDRk
LFDRk
¼
pE θjxk ðÞ
pN θjxk ðÞ
|ﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄ}
posterior odds
¼
LE θjxk ðÞ
LN θjxk ðÞ
|ﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄ}
Bayes factor
⋅
1−π0
π0 |ﬄ{zﬄ}
prior odds
and rearranging terms to obtain
LFDRk ¼
π0
1−π0
exp
Bk
2
  
þ
π0
1−π0
ð4Þ
Use of Equation (4) required an estimate of π0 which
we obtained from the following relation
pB k > 0 ðÞ ¼ pN Bk > 0 ðÞ π0 þ pE Bk > 0 ðÞ 1−π0 ðÞ ;
ð5Þ
where pN(Bk >0) and pE(Bk >0) denoted the probability
of a positive scaled Bayes factor if the data was generated
under the non-epitope and epitope models, respectively.
The probability p(Bk> 0) can be approximated as the
proportion of observed scaled Bayes factors greater than
zero for any particular serum sample. To approximate
pN(Bk>0), we permuted the assignment of ID50 titers to
the pseudoviruses and recorded the proportion of scaled
Bayes factors greater than zero. In this respect, we con-
sidered only sites at which the frequency of the most
prevalent amino acid was <95%, since invariant sites do
not provide evidence for either model. The median
proportion over 100 such permutations was used as an
estimate of pN(Bk> 0). (The mean proportion was not
substantively different.) These estimates are reported in
Additional file 2: Table S2. For a suitable choice of pE
(Bk >0 ) , π0 may be computed from Equation (5) and
used to obtain the LFDR for a given Bayes factor. We
set pE(Bk > 0 ) = 1t oo b t a i na nu p p e rb o u n do nt h e
LFDR. Our reported false discovery rates should therefore
be regarded as conservative.
Conformational epitope prediction
The method described above can identify individual sites
associated with neutralization titer. A set of such predic-
tions in close proximity on the primary sequence pro-
vides evidence for a linear B cell epitope. Similarly, a set
of predictions clustered on the three-dimensional struc-
ture provides evidence for a conformational epitope. For
any set of amino acids, C, the likelihood that these sites
all support the epitope model and that all other sites are
generated under the non-epitope model may be com-
puted as
LC ðÞ ¼∏
k∈C
LEðθjxkÞ ∏
k∉C
LN θ xkÞ j ð
We introduced a simple spherical model of an epitope
that can identify sets of sites that support the epitope
model and are clustered in three-dimensional space. A
Metropolis algorithm was used to explore the posterior
density of the location and size of the sphere (see [57]
for a general description of the Metropolis algorithm).
The posterior probability that any three-dimensional lo-
cation lies within the conformational epitope was then
computed as the proportion of times that the location
falls within the sampled spheres.
We implemented the Metropolis algorithm in Mathe-
matica 8, using the 2B4C Protein Data Bank structure
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with HyPhy [54]. We assumed a uniform prior on the
three-dimensional coordinate vector defining the centre
of the sphere and a gamma prior, π(r), on the radius r of
the sphere with a shape parameter of 2 Å and a scale
parameter of 4 Å (mean of 8 Å). At the outset, a sphere
was generated by randomly selecting an amino acid as
the centre of the sphere and drawing a random radius
from its prior distribution. A new sphere was proposed
by independently drawing each of the three coordinates
and the radius from a normal distribution centered on
the parameter value of the current sphere with a fixed
standard deviation of 3 Å. A move from the current
sphere C with radius r to a new sphere C’ with a radius
r’ located elsewhere in the protein was accepted with
probability
α ¼ min
LC 0 ðÞ π r0 ðÞ
LC ðÞ π r ðÞ
;1
  
:
A subsequent sphere was then proposed as described
above and the process repeated until the Markov chain
converged to its stationary distribution. We used a burn-
in period of 10 000 iterations, after which spheres were
sampled from their posterior distribution at every 100th
iteration for 500 000 iterations.
Identification of coevolving sites
We used a modified version of the evolutionary network
model of Poon et al. [38] to identify co-evolving sites.
The evolutionary events that generated the observed
sequence alignment were reconstructed by maximum
likelihood under an MG94 × GTR model of codon evo-
lution. For each of the terminal branches, the codon
sites that were inferred to have undergone nonsynon-
ymous substitutions were encoded with a 1 and other
codon sites were encoded with a 0. This produced an
augmented dataset with each terminal branch corres-
ponding to an independent observational vector of the
substitution events that occurred along that branch at
each codon site and the neutralization titer observed at
the tip of the branch. These data were used to construct
a Bayesian network under the assumption of log-normal
titers. In this context, a Bayesian network is a representa-
tion of the joint probability distribution over neutralization
titer and the substitution events at all codon positions. The
network may be visualized as a graph with nodes repre-
senting variables (codon sites and neutralization titer) and
edges indicating dependencies between the variables. The
evidence in support of each relationship is quantified with
a posterior probability. Importantly, by considering the
complete distribution of the data, a Bayesian graphical
model is able to resolve conditional dependencies, where
one variable is related to another only through a mutual
relationship with a third variable. The model was imple-
mented in HyPhy with an experimental batch file provided
by Dr AFY Poon.
Phylogenetically-corrected Fisher’s exact tests
We compared the predictions of our evolutionary model
to those of the signature detection method of Gnanakaran
et al. [15]. Briefly, this method uses phylogenetically-
corrected Fisher’s exact tests to identify significant associ-
ations between amino acid changes along the terminal
branches of the viral phylogeny and a binary classification
of neutralization phenotypes at the tips of the branches.
Three neutralization classification schemes were consid-
ered; viruses were classified as neutralization resistant if
their ID50 titers were less than the first quartile, less than
the median or less than the third quartile. Ancestral
sequences were reconstructed by maximum likelihood
using a general time reversible model of nucleotide evolu-
tion with site-specific rate heterogeneity. For each possible
ancestral amino acid at each site, a contingency table was
constructed to test whether the proportion of neutrali-
zation sensitive viruses was significantly different between
extant viruses that contained the ancestral amino acid at
the site versus those that did not. Due to the large number
of tests performed, q-values were used to judge statis-
tical significance while controlling the false positive
rate. All sites with at least one q ≤ 1/3 (twice as likely
t ob eat r u ep o s i t i v ea saf a l s ep o s i t i v e )w e r ec o n s i d -
ered as worthy of further investigation. Only the
smallest q-value obtained for each site is reported in
Additional file 2: Table S3.
Experimental validation
A subset of the residues predicted to be associated with
neutralization sensitivity were tested for their effect on
neutralization sensitivity in one to three sensitive enve-
lope backbones per serum sample using site-directed
mutagenesis. Residues of interest were mutated to
alanine in all cases except for position 169, which was
mutated to glutamic acid as described previously [34].
Mutagenesis was performed using the Stratagene Quick-
Change II kit (Stratagene) and confirmed by sequence
analysis. Envelope-pseudotyped viruses from mutated and
parental envelope clones were obtained by co-transfecting
the envelope plasmid with pSG3ΔEnv using Fugene
transfection reagent (Roche) into 293 T cells as previously
described [7]. Neutralization was measured by a reduction
in luciferase gene expression after single round infection
of JC53bl-13 cells with envelope-pseudotyped viruses [7].
Titers were calculated as the reciprocal plasma dilution
(ID50) causing 50% reduction of relative light units. The
effect of mutations on neutralization sensitivity was calcu-
lated as a fold change in neutralization titers of the mutant
virus compared to the unmutated parental clone. A model
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corresponding site produced at least a twofold reduction
in ID50 titer in at least one backbone.
Software availability
The likelihoods of the evolutionary models were com-
puted on a computer cluster using the parallel process-
ing capabilities of HyPhy and the R Language and
Environment for Statistical Computing. We are currently
working on an online tool to implement this method-
ology. All computer code is freely available from the cor-
responding author.
Availability of supporting data
The data set supporting the results of this article is pro-
vided in Additional file 3: Dataset S1.
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Additional file 1: Figure S1. Model predictions for CAP256. Scaled
Bayes factors using the (A) autologous CAP256, (B) CAP210 and (C)
CAP45 reference sequences. (D) Bayesian evolutionary-network model. (E)
Posterior probabilities of a conformational epitope using the three-
dimensional model with a ConC reference sequence. The posterior
probabilities are shaded as described in the legend for Figure 4B. There is
some evidence of a conformational epitope in the V3 region (posterior
probabilities as high as 0.367). Figure S2. Model predictions for CAP8.
Scaled Bayes factors using the (A) ConC, (B) Q23 and (C) TRO reference
sequences. (D) Bayesian evolutionary-network model. (E) Posterior prob-
abilities of a conformational. Figure S3. Model predictions for CAP257.
Scaled Bayes factors using the (A) ConC and (B) Q842 reference
sequences. (C) Bayesian evolutionary-network model. (D) Posterior prob-
abilities of a conformational epitope using the three-dimensional model
with a ConC reference sequence. The posterior probabilities are shaded
as described in the legend for Figure 4B. There is some evidence of a
conformational epitope in the V3 region (posterior probabilities as high
as 0.361). Figure S4. Model predictions for CAP255. Scaled Bayes factors
using the (A) autologous CAP255, (B) TRO and (C) Q23 reference
sequences. Figure S5. Model predictions for CAP177. Scaled Bayes
factors using the (A) ConC, (B) Q23 and (C) TRO reference sequences.
(D) Bayesian evolutionary-network model. Figure S6. Model predic-
tions for CAP206. Scaled Bayes factors using the (A) ZM197, (B)
autologous CAP206, (C) CAP45, (D) Q23, (E) COT6 and (F) TRO refer-
ence sequences. (G) Bayesian evolutionary-network model. Figure S7.
Model predictions for CAP248. Scaled Bayes factors using the (A)
ConC, (B) CAP45 and (C) DU156 reference sequences. (D) Bayesian
evolutionary-network model. Figure S8. Scaled Bayes factors for the
CAP256 serum obtained after imputing ancestral titers with the
median observed titer and titers reconstructed with Felsenstein’s
method.
Additional file 2: Table S1. Reference sequences. Table S2. Estimates
used to compute LFDRs. Table S3. Significant associations obtained with
the method of Gnanakaran et al. [15]. Table S4. Sites with scaled Bayes
factors ≥6 using reconstructed titers.
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